{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113762.1.4.1146.1602",
  "meta" : {
    "versionId" : "8",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "CSTE Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-keyWord",
      "valueString" : "HIV,Trigger"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2024-06-03"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2022-01-18"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1602",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113762.1.4.1146.1602"
    }
  ],
  "version" : "20220118",
  "name" : "HIVInfectionARVPostattachmentInhibitorsRXNORM",
  "title" : "HIV Infection (ARV Postattachment Inhibitors) (RXNORM)",
  "status" : "retired",
  "experimental" : false,
  "date" : "2022-01-18T01:02:46-05:00",
  "publisher" : "CSTE Steward",
  "description" : "All prescribable medication formulations represented using either a \"generic\" or \"brand-specific\" concept. This includes RxNorm codes whose Term Type is SCD (semantic clinical drug), or SBD (semantic brand drug). GPCK (generic pack), BPCK (brand pack), SCDG (semantic clinical drug group), SBDG (semantic brand drug group), SCDF (semantic clinical drug form), IN (ingredient) or SBDF (semantic brand drug form) are NOT included in this value set. This value set does not include oral administration concepts, only concepts for medications administered specifically for overdose (injection, nasal).",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: This set of values contains codes for prescribable medications for HIV),(Data Element Scope: Medications that were administered, ordered or prescribed.),(Inclusion Criteria: ARV Postattachment Inhibitors),(Exclusion Criteria: SBDG (semantic brand drug group), SCDF (semantic clinical drug form), or SBDF (semantic brand drug form).)",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "concept" : [
          {
            "code" : "2043317",
            "display" : "1.33 ML ibalizumab-uiyk 150 MG/ML Injection"
          },
          {
            "code" : "2043322",
            "display" : "1.33 ML ibalizumab-uiyk 150 MG/ML Injection [Trogarzo]"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:27ce548f-46e2-4d6c-af38-ec11ae0a7f41",
    "timestamp" : "2024-06-14T11:55:03-04:00",
    "total" : 2,
    "contains" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "05062024",
        "code" : "2043317",
        "display" : "1.33 ML ibalizumab-uiyk 150 MG/ML Injection"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "05062024",
        "code" : "2043322",
        "display" : "1.33 ML ibalizumab-uiyk 150 MG/ML Injection [Trogarzo]"
      }
    ]
  }
}
